business / news / / The Economic Times
Generic versions of Novo Nordisk's semaglutide are now available at lower prices.
Generic semaglutide captured 33% of India's GLP-1 market within days of launch in March.
KEY POINTS
- Mounjaro's market share in India dropped from 71% to 64% after generics entered.
- Torrent Pharmaceuticals now holds an 8% share in India's semaglutide market, second only to Novo Nordisk.
- Indian generics are priced as low as 1,290 rupees, over 85% cheaper than the original.
- Semaglutide drug volumes in India more than doubled in March compared to the previous month.
COMPANIES
Summarized by Newsio from The Economic Times. How we summarize →